Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2021 · 10-K
Revenue$27.36M$27.36M−64.1% vs Q4 2020 Net Income-$25.03M-$25.03MN/M vs Q4 2020 EPS Diluted-$0.73-$0.73N/M vs Q4 2020 Gross Profit-$1,333,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$36,198,000+60.3% Free Cash Flowderived$35,683,000+69.1% Margins · derivedGross margin-4.9%−62.9 pt vs Q4 2020
Operating margin-124.7%−144.4 pt vs Q4 2020
Net margin-91.5%−100.6 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end